

### Laufende Klinische Studien

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	PI	Co- Investigator	Status / Start / End
<b>Prof. Dr. Dagmar Simon</b>						
Urticaria	CDX0159-12	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of <b>Barzolvolimab</b> in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (Embarq – CSU1)	PPD	Prof. Simon	S. Radonjic	in Planung
Atopische Dermatitis	Incyte_TRuE-AD4 INCB 1824_326	<u>Topical <b>Ruxolitinib</b> Evaluation in Atopic Dermatitis Study (TRuE-AD4)</u> A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis.	Incyte Corporation	Prof. Simon		in Planung
Prurigo Nodularis	INCB54707-305	<b>Povorocitinib</b>	Incyte Corporation	Prof. Simon		in Planung
Atopische Dermatitis	ADHope 2 M-1723-34	Phase 3b Studie zu <b>Lebrikizumab</b> (antiIL-13) bei Atopic Dermatitis	Almirall	Prof. Simon		in Planung
Atopische Dermatitis	TREAT	Treatment and medical care of patients with moderate-to-severe atopic dermatitis - Swiss national clinical registry TREAT Switzerland	SGDV	Prof. Simon		Rekrutiert Patienten
Prurigo Nodularis	RD.06.SPR.202699	A randomized, Double-blind, Placebo-Controlled Study to assess the Efficacy and Safety of <b>Nemolizumab</b> (CE14152) in Subjects with Prurigo Nodularis	Galderma	Prof. Simon		Rekrutiert Patienten

## Dermatologische Klinik Inselspital Bern Studienübersicht

Prof. Dr. Robert Hunger						
Hidradenitis suppurativa	Moonlake (M20456?)	Immunotherapeutics / Sonelokimab		Prof. Hunger		Beginn Ende 2025 oder später
Hidradenitis suppurativa	M23-698	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of <b>Upadacitinib</b> in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	Abbvie	Prof. Hunger		Rekrutiert Patienten
Hidradenitis suppurativa	BI 1368-0098	Randomized, double-blind, placebo-controlled, Phase II b / Phase III study to evaluate the efficacy and safety of <b>Spesolimab</b> in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.	Boehring Ingelheim	Prof. Hunger		Rekrutiert Patienten
Advanced Cutaneous Squamous Cell Carcinoma	CemiSkin	Nichtinterventionelle multizentrische, longitudinale 2-Kohorten Studie zur Wirksamkeit, Sicherheit und Quality of Life (QoL) bei Patienten mit fortgeschrittenem kutanen Plattenepithelkarzinom (adCSCC, Advanced Cutaneous Squamous Cell Carcinoma), die mit <b>Cemiplimab</b> (prospektive Kohorte) oder anderen Therapieansätzen behandelt werden	Sanofi-Aventis	Prof. Hunger	Dr. Benzaquin	Rekrutiert Patienten
Melanoma	NEO-DREAM	An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of <b>Daromun</b> (L191L2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients	Philochem	Prof. Hunger		Rekrutiert Patienten
Melanoma	BERING_MELANOMA	<b>Encorafenib + Binimetinib</b> in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma; a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland <b>Binimetinib plus Encorafenib Real life Investigation of Next Generation Melanoma treatment</b>	Pierre Fabre Pharma AG/Alcedis	Prof. Hunger	Dr. Lamos Dr. Bossart	Rekrutiert Patienten
Hidradenitis suppurativa	HS Register	The goal of the Hidradenitis suppurativa registry (HSR) is to evaluate the long-term course, safety clinical outcomes and health related quality of life of patients with Hidradenitis suppurativa (HS). Patient will be enrolled in the HSR with a confirmed HS diagnosis only and treated in the participating centers. <b>Patients will remain in the HSR for 3 years, regardless of subsequent therapy.</b>	SHSF	Prof. Hunger		Rekrutiert Patienten

## Dermatologische Klinik Inselspital Bern Studienübersicht

Prof. Dr. Nikhil Yawalkar						
<b>Paradoxical Psoriasis</b>	<b>TYPP/TYK2</b>	<b>TYK2 inhibition in paradoxical psoriasis (TYPP)</b> A randomized, double-blind, placebo-controlled multi-center study evaluating the effect of <b>Deucravacitinib</b> on severity of psoriasis in patients with paradoxical psoriasis (phase II/III)	<b>CHUV</b>	Prof. Yawalkar		in Planung
<b>Genital Psoriasis</b>	<b>CzATCH</b>	Observational, non-interventional, prospective, multinational (Austria, Switzerland, and the Czech Republic), multicentric, open, uncontrolled study on the effectiveness and safety of <b>Tildrakizumab</b> in the treatment of plaque psoriasis with a manifestation in the genital area in clinical routine according to the summary of product characteristics (SmPC).	<b>Almirall/ CW Research &amp; Management</b>	K. Heidemeier	Prof. Yawalkar A. Rabuffetti	Rekrutiert Patienten
<b>Psoriasis (GPP)</b>	<b>SPESOLIMAB (Compassionate Use Program)</b>	Open label expanded access program (EAP) or compassionate use program (CUP) or named patient use (NPU) of intravenous <b>Spesolimab</b> 900 mg in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare	<b>Boehringer Ingelheim</b>	Prof. Yawalkar / K. Heidemeyer	Dr. Heidemeyer	Rekrutiert Patienten
<b>Psoriasis vulgaris</b>	<b>SDNTT</b>	Psoriasis Register-Studie / Long-Term Benefits of Systemic Psoriasis Therapy	<b>SGDV &amp; Uni Zürich</b>	Prof. Yawalkar	diverse Ärzte siehe separate Liste	Rekrutiert Patienten
<b>Weitere</b>						
<b>Chronic Pruritus</b>	<b>CP-derma1</b>	Multicenter case-control study on <b>risk factors for generalised chronic pruritus</b> , with focus on patients' comorbidities and medications intake		Dr. Cazzaniga	Dr. Benzaquen	Rekrutiert Patienten